Drugs that contain Deutetrabenazine
1. List of Austedo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(8 years from now) | |
| US9550780 | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8524733
(Pediatric) | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(8 years from now) | |
| US9814708 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
| US9296739 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
| US9233959 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
|
US9550780
(Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) | |
|
US9814708
(Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) | |
|
US9233959
(Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) | |
|
US9296739
(Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) | |
| US11446291 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(13 years from now) | |
| US10959996 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(13 years from now) | |
| US11357772 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(13 years from now) | |
|
US11357772
(Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(13 years from now) | |
|
US10959996
(Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(13 years from now) | |
| US11179386 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(15 years from now) | |
|
US11179386
(Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
| New Chemical Entity Exclusivity (NCE) | Apr 3, 2022 |
| M | Jun 24, 2024 |
| Pediatric Exclusivity (PED) | Oct 3, 2024 |
NCE-1 date: October, 2023
Market Authorisation Date: 03 April, 2017
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic